Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacological and Expectation Effects in Antidepressant Discontinuation
NCT05191277Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Aug 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of antidepressant (TDDS/ODF) in major depressive disorder (MDD) (4 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Discontinuation Related Signs and Symptoms Scale at 13 weeks. Started Aug 2022; status: completed.
02
Drugs
antidepressant (TDDS/ODF)
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05191277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05191277.